|Pharmaceuticals and the WTO TRIPS Agreement: Questions and answers (UNAIDS - WHO/EDM, 2000, 5 p.)|
Further information on intellectual property rights for pharmaceuticals and on aspects of access to HIV/AIDS related drugs are available in the following references and web links:
· Patent situation of HIV/AIDS related drugs in 80 countries
Intellectual property rights and pharmaceuticals
· WHO/EDM. Globalization, patents and drugs - an annotated bibliography. Health Economics and Drugs, EDM Series No. 9. Geneva: World Health Organization; 1999 (WHO/EDM/PAR/99.6).
· WHO/EDM. Globalization and access to drugs - perspectives on the WTO TRIPS Agreement. Health Economics and Drugs, EDM Series No.7. Geneva: World Health Organization; 1999 (WHO/EDM/98.9 Revised).
· Otten A. The implications of the TRIPS Agreement for the protection of pharmaceutical inventions. WHO Drug Information. 1997(11):1.
· UNCTAD. The TRIPS Agreement and developing countries. Geneva: United Nations Conference on Trade and Development; 1996 (UNCTAD/ITE/1).
· South Centre. The TRIPS Agreement - a guide for the South. Geneva: South Centre; 1997.
· IFPMA. The question of patents. Geneva: International Federation of Pharmaceutical Manufacturers Associations; 1998.
· Health Action International. Power, patents and pills - an examination of GATT/WTO policies and essential drug policies. Seminar Report. Amsterdam: HAI-Europe; 1997.
Access to HIV/AIDS-related drugs
· Technical update: Access to drugs. UNAIDS Best Practice Collection, 1998.
· WHO/DAP. Guidelines on standard treatments and essential drugs for HIV-related conditions. Access to HIV-related drugs. Geneva: World Health Organization, 1997.
· WHO/UNAIDS. The implications of antiretroviral treatment. Geneva: World Health Organization; 1997 (WHO/ASD/97.2).